Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Haloprogin: Difference between pages
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 447739967 of page Haloprogin for the Chem/Drugbox validation project (updated: 'DrugBank'). |
Entranced98 (talk | contribs) Importing Wikidata short description: "Chemical compound" |
||
| Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Haloprogin|oldid=447739967}} 447739967] of page [[Haloprogin]] with values updated to verified values.}} |
|||
{{Redirect|Polik}} |
|||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = |
| verifiedrevid = 461766483 |
||
| IUPAC_name = 1,2,4- |
| IUPAC_name = 1,2,4-Trichloro-5-[(3-iodoprop-2-yn-1-yl)oxy]benzene |
||
| image = Haloprogin. |
| image = Haloprogin.svg |
||
| image2 = |
| image2 = |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = <!-- |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
||
| legal_US_comment = Not available |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|||
| legal_status = |
| legal_status = |
||
| routes_of_administration = Topical |
| routes_of_administration = [[Topical medication|Topical]] |
||
<!--Pharmacokinetic data--> |
<!--Pharmacokinetic data--> |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 777-11-7 |
| CAS_number = 777-11-7 |
||
| ATC_prefix = D01 |
| ATC_prefix = D01 |
||
| Line 43: | Line 44: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=9 | H=4 | Cl=3 | I=1 | O=1 |
| C=9 | H=4 | Cl=3 | I=1 | O=1 |
||
| molecular_weight = 361.39 g/mol |
|||
| smiles = Clc1cc(OCC#CI)c(Cl)cc1Cl |
| smiles = Clc1cc(OCC#CI)c(Cl)cc1Cl |
||
| InChI = 1/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
|||
| InChIKey = CTETYYAZBPJBHE-UHFFFAOYAB |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
| StdInChI = 1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
||
| Line 53: | Line 51: | ||
| StdInChIKey = CTETYYAZBPJBHE-UHFFFAOYSA-N |
| StdInChIKey = CTETYYAZBPJBHE-UHFFFAOYSA-N |
||
| melting_point = 113.5 |
| melting_point = 113.5 |
||
| solubility = |
| solubility = Insoluble |
||
}} |
}} |
||
'''Haloprogin''' is an [[Antifungal medication|antifungal]] drug used to treat [[athlete's foot]] and other [[fungus|fungal]] [[infection]]s.<ref name="pmid161212">{{cite journal | vauthors = Rudolph RI | title = Haloprogin as treatment for fungal infections | journal = Clinical and Experimental Dermatology | volume = 4 | issue = 4 | pages = 548 | date = December 1979 | pmid = 161212 | doi = 10.1111/j.1365-2230.1979.tb01656.x | s2cid = 71471801 }}</ref> It is marketed in creams under the trade names '''Halotex''', '''Mycanden''', '''Mycilan''', and '''Polik'''. |
|||
==Action== |
|||
Haloprogin was previously used in 1% topical creams as an antifungal agent. It was marketed [[Over-the-counter drug|over-the-counter]] primarily to treat [[tinea]] infections of the [[skin]]. The mechanism of action is unknown.<ref>{{cite web |
|||
| title =Haloprogin |
|||
| work =Drugs@FDA |
|||
| publisher =[[Food and Drug Administration]] |
|||
| url = http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=HALOTEX |
|||
| access-date = 2007-02-17 }}</ref> |
|||
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.<ref>{{cite web |
|||
| title = Haloprogin |
|||
| work = DrugBank |
|||
| publisher = University of Alberta |
|||
| date =Nov 6, 2006 |
|||
| url =http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD01011.txt |
|||
| access-date = 2007-02-17 }}</ref> |
|||
==References== |
|||
<references /> |
|||
{{Antifungals}} |
|||
{{Xenobiotic-sensing receptor modulators}} |
|||
[[Category:Alkyne derivatives]] |
|||
[[Category:Antifungals]] |
|||
[[Category:Chloroarenes]] |
|||
[[Category:Organoiodides]] |
|||
{{antiinfective-drug-stub}} |
|||
{{dermatologic-drug-stub}} |
|||